MedTrace Logo

Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects

NCT03358901 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-12-06

No results posted yet for this study

Summary

The study is designed to determine the safety, tolerability, and pharmacokinetics in healthy subjects with multiple intravenous administration of the neuroprotectant YC-6 compared to placebo.

Conditions

Interventions

DRUG

YC-6

DRUG

Vehicle

Sponsors & Collaborators

  • Xiuhe Medical Technique Co.,Ltd.

    collaborator UNKNOWN

  • Guangzhou Cellprotek Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Bei Hu, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03358901 on ClinicalTrials.gov